MCID: UTR033
MIFTS: 49

Uterine Corpus Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Cancer

MalaCards integrated aliases for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer 12 15 73
Malignant Uterine Corpus Neoplasm 73
Corpus Uteri Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9460
ICD10 33 C54 C54.9
ICD9CM 35 182
NCIt 50 C3556
SNOMED-CT 68 93718007

Summaries for Uterine Corpus Cancer

Disease Ontology : 12 A uterine cancer that is located in the uterine corpus.

MalaCards based summary : Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to uterine body mixed cancer and uterine corpus serous adenocarcinoma. An important gene associated with Uterine Corpus Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and ovary, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Uterine Corpus Cancer

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 167)
# Related Disease Score Top Affiliating Genes
1 uterine body mixed cancer 30.9 ERBB2 FBXW7 PGR PIK3CA PIK3R2 PPP2R1A
2 uterine corpus serous adenocarcinoma 30.9 BRCA1 ERBB2 FBXW7 PIK3CA PPP2R1A TP53
3 endometrial cancer 30.4 BRCA1 ERBB2 ESR1 MYC PGR PIK3CA
4 breast cancer 28.7 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
5 uterine corpus endometrial carcinoma 11.2
6 adenomyoma of uterine corpus 11.2
7 uterine corpus sarcoma 11.2
8 mixed endometrial stromal and smooth muscle tumor 11.2
9 esophagus adenocarcinoma 10.3 ERBB2 TP53
10 hypertrichosis universalis congenita, ambras type 10.3 MYC TP53
11 suppressor of tumorigenicity 3 10.3 MYC TP53
12 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
13 prostate squamous cell carcinoma 10.2 PPP2R1A TP53
14 vulva basal cell carcinoma 10.2 ERBB2 MYC
15 pleomorphic adenoma carcinoma 10.2 ERBB2 TP53
16 acneiform dermatitis 10.2 ERBB2 PIK3CA
17 non-proliferative fibrocystic change of the breast 10.2 ERBB2 TP53
18 hemimegalencephaly 10.2 MYC PIK3CA
19 spinal cord glioma 10.2 TP53 TUBB3
20 anterior cranial fossa meningioma 10.2 PGR TP53
21 ovarian carcinosarcoma 10.2 ERBB2 TUBB3
22 adult hepatocellular carcinoma 10.2 PIK3CA TP53
23 rare adenocarcinoma of the breast 10.2 PIK3CA TP53
24 endometrium carcinoma in situ 10.2 PGR TP53
25 malignant spiradenoma 10.2 PIK3CA TP53
26 scirrhous adenocarcinoma 10.2 ERBB2 PGR
27 breast apocrine carcinoma 10.2 ERBB2 PGR
28 marcus gunn phenomenon 10.2 MYC TUBB3
29 b cell prolymphocytic leukemia 10.2 MYC TP53
30 intracystic papillary adenoma 10.2 ERBB2 PGR
31 megaesophagus 10.2 MYC TP53
32 breast metaplastic carcinoma 10.2 ERBB2 PGR
33 cutis marmorata telangiectatica congenita 10.2 PIK3CA PIK3R2
34 progesterone-receptor negative breast cancer 10.1 ERBB2 PGR
35 megalencephaly-capillary malformation-polymicrogyria syndrome 10.1 PIK3CA PIK3R2
36 breast malignant phyllodes tumor 10.1 PGR TP53
37 stomach disease 10.1 ERBB2 TP53 TUBB3
38 central nervous system cancer 10.1 MYC TP53 TUBB3
39 tuberculous salpingitis 10.1 BRCA1 ERBB2
40 nervous system cancer 10.1 MYC TP53 TUBB3
41 olfactory groove meningioma 10.1 PGR TP53
42 gastrointestinal system disease 10.1 ERBB2 MYC TP53
43 breast squamous cell carcinoma 10.1 ERBB2 PIK3CA TP53
44 glioma susceptibility 1 10.1 ERBB2 TP53
45 myasthenic syndrome, congenital, 14 10.1 MYC PIK3CA
46 ovary adenocarcinoma 10.1 ERBB2 PIK3CA TP53
47 respiratory system disease 10.1 PIK3R2 TP53 TUBB3
48 renal cell carcinoma, papillary, 1 10.1 ERBB2 PIK3CA TP53
49 bartholin's gland disease 10.1 PGR TP53
50 oral cavity cancer 10.1 ERBB2 PIK3CA TP53

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:



Diseases related to Uterine Corpus Cancer

Symptoms & Phenotypes for Uterine Corpus Cancer

GenomeRNAi Phenotypes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.6 PIK3CA
2 Decreased viability GR00173-A 10.6 PIK3R2
3 Decreased viability GR00221-A-1 10.6 ESR1 PIK3CA PIK3R2 MYC
4 Decreased viability GR00221-A-2 10.6 BRCA1 ESR1 PIK3CA PIK3R2
5 Decreased viability GR00221-A-3 10.6 BRCA1 MYC ERBB2
6 Decreased viability GR00221-A-4 10.6 ESR1 PIK3CA PIK3R2 ERBB2
7 Decreased viability GR00301-A 10.6 BRCA1 PIK3R2
8 Decreased viability GR00402-S-2 10.6 BRCA1 ESR1 PIK3CA PIK3R2 MYC ERBB2
9 Decreased viability in esophageal squamous lineage GR00235-A 9.56 BRCA1 ERBB2 ESR1 PGR PIK3CA PIK3R2
10 Increased cell death HMECs cells GR00103-A-0 9.17 BRCA1 FBXW7 MYC PGR PIK3CA PPP2R1A

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
2 cardiovascular system MP:0005385 10.22 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
3 cellular MP:0005384 10.21 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
4 behavior/neurological MP:0005386 10.18 BRCA1 ERBB2 ESR1 MYC PGR PIK3CA
5 endocrine/exocrine gland MP:0005379 10.18 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
6 mortality/aging MP:0010768 10.17 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
7 growth/size/body region MP:0005378 10.16 BRCA1 ERBB2 ESR1 FBXW7 MYC PIK3CA
8 embryo MP:0005380 10.14 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
9 integument MP:0010771 10.08 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
10 neoplasm MP:0002006 10.07 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
11 digestive/alimentary MP:0005381 10.02 BRCA1 ERBB2 ESR1 FBXW7 MYC TP53
12 muscle MP:0005369 10.01 BRCA1 ERBB2 ESR1 MYC PGR PIK3CA
13 adipose tissue MP:0005375 9.98 BRCA1 ESR1 MYC PIK3CA TP53
14 limbs/digits/tail MP:0005371 9.93 BRCA1 ERBB2 ESR1 MYC PGR TP53
15 nervous system MP:0003631 9.92 BRCA1 ERBB2 ESR1 FBXW7 MYC PIK3CA
16 normal MP:0002873 9.86 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
17 reproductive system MP:0005389 9.76 BRCA1 ERBB2 ESR1 MYC PGR PIK3CA
18 respiratory system MP:0005388 9.43 BRCA1 ERBB2 ESR1 FBXW7 TP53 TUBB3
19 skeleton MP:0005390 9.17 BRCA1 ERBB2 ESR1 MYC PGR PIK3CA

Drugs & Therapeutics for Uterine Corpus Cancer

Drugs for Uterine Corpus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
6
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
7
Doxil Approved June 1999 Phase 3,Phase 1 31703
8 Adjuvants, Immunologic Phase 3,Phase 1
9 Immunologic Factors Phase 3,Phase 2,Phase 1
10 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
12 Antimitotic Agents Phase 3,Phase 2,Phase 1
13 Topoisomerase Inhibitors Phase 3,Phase 1
14 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
15 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
16 Hypoglycemic Agents Phase 2, Phase 3
17
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
18
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
19
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
20
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
21
Tamoxifen Approved Phase 2 10540-29-1 2733526
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3
23
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
24
Dasatinib Approved, Investigational Phase 2,Phase 1 302962-49-8 3062316
25
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
26
Nivolumab Approved Phase 2,Phase 1 946414-94-4
27
Olaparib Approved Phase 2 763113-22-0 23725625
28
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444
29
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
30
Pertuzumab Approved Phase 2 145040-37-5, 380610-27-5 2540
31
Osimertinib Approved Phase 2 1421373-65-0
32
Adenosine Approved, Investigational Phase 2 58-61-7 60961
33
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
34
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
35
Trametinib Approved Phase 2 871700-17-3 11707110
36
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
37
Racepinephrine Approved Phase 2 329-65-7 838
38
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
39
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5330286 5005498
40
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
41
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
42
Polyestradiol phosphate Approved Phase 2 28014-46-2
43
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
44 Estradiol valerate Approved, Investigational, Vet_approved Phase 2 979-32-8
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
46
Cediranib Investigational Phase 2 288383-20-0 9933475
47
Maleic acid Experimental Phase 2 110-16-7 444266
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
49 Antineoplastic Agents, Hormonal Phase 2
50 Anti-Infective Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
2 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
4 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
5 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
6 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
7 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
8 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
9 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
10 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
11 Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer Unknown status NCT01041027 Phase 2 Paclitaxel;Carboplatin
12 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Completed NCT00729586 Phase 2 Megestrol Acetate;Tamoxifen Citrate;Temsirolimus
13 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
14 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
15 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2 Carboplatin;Cisplatin;Paclitaxel
16 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
17 Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer Recruiting NCT03367741 Phase 2 Cabozantinib
18 Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors Recruiting NCT03367923 Phase 2
19 Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer Recruiting NCT03660826 Phase 2 Cediranib Maleate;Olaparib
20 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
21 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting NCT02465060 Phase 2 Adavosertib;Afatinib;Binimetinib;Capivasertib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib
22 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting NCT00006903 Phase 2 Fulvestrant
23 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Active, not recruiting NCT00977574 Phase 2 Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
24 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2 Sunitinib Malate
25 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Suspended NCT01935934 Phase 2 Cabozantinib S-malate
26 Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia Terminated NCT00503581 Phase 2 Megestrol Acetate
27 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005840 Phase 1 Paclitaxel;Cisplatin
28 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00005830 Phase 1 Doxorubicin Hydrochloride;Cisplatin
29 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Completed NCT01522820 Phase 1 Sirolimus
30 Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Completed NCT00575952 Phase 1 Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
31 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed NCT01440998 Phase 1 Carboplatin;Dasatinib;Paclitaxel
32 Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery Completed NCT00410553 Phase 1 Eribulin Mesylate;Gemcitabine Hydrochloride
33 Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Recruiting NCT01970722 Phase 1 cisplatin;carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride;gemcitabine hydrochloride
34 Adavosertib, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer Recruiting NCT03345784 Phase 1 Adavosertib;Cisplatin
35 VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Recruiting NCT03120624 Phase 1 Technetium Tc-99m Sodium Pertechnetate
36 Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Recruiting NCT03508570 Phase 1
37 Physical Activity Behavioral Intervention in Obese Endometrial Cancer Survivors Unknown status NCT02575872 Not Applicable
38 Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia Completed NCT02342730 Not Applicable
39 Prognostic Biomarkers in Patients With Endometrial Cancer Completed NCT01208467
40 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
41 Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors Completed NCT03198286 Not Applicable
42 Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer Completed NCT01098630
43 Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer Recruiting NCT03042897 Not Applicable
44 Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners Recruiting NCT03112668 Not Applicable
45 Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies Recruiting NCT02578888 Not Applicable
46 Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery Active, not recruiting NCT02315469
47 Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Active, not recruiting NCT00956670 Not Applicable
48 Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Not yet recruiting NCT01164735
49 Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer Not yet recruiting NCT01198171
50 Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer Not yet recruiting NCT01344837

Search NIH Clinical Center for Uterine Corpus Cancer

Genetic Tests for Uterine Corpus Cancer

Anatomical Context for Uterine Corpus Cancer

MalaCards organs/tissues related to Uterine Corpus Cancer:

41
Bone, Lung, Ovary, Spinal Cord, Prostate, Smooth Muscle, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Cancer:

19
The Uterine Corpus

Publications for Uterine Corpus Cancer

Articles related to Uterine Corpus Cancer:

(show all 30)
# Title Authors Year
1
Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women. ( 28805629 )
2017
2
Reply to "Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women". ( 28805626 )
2017
3
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. ( 27894165 )
2017
4
Incidence and lifetime risk of uterine corpus cancer in Taiwanese women from 1991 to 2010. ( 28254229 )
2017
5
Laparoscopic Repair of Vaginal Evisceration after Abdominal Hysterectomy for Uterine Corpus Cancer: A Case Report and Literature Review. ( 28502966 )
2017
6
Gemella morbillorum bacteremia following total laparoscopic hysterectomy for uterine corpus cancer. ( 30254882 )
2017
7
A prediction model of survival for patients with bone metastasis from uterine corpus cancer. ( 27655906 )
2016
8
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? ( 27261326 )
2016
9
Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer. ( 25486104 )
2015
10
Comorbidity is an independent prognostic factor in women with uterine corpus cancer: a nationwide cohort study. ( 24443826 )
2014
11
State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. ( 23125334 )
2013
12
Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer. ( 21136177 )
2011
13
Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. ( 21508766 )
2011
14
Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. ( 21705925 )
2011
15
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. ( 20966700 )
2010
16
Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. ( 20142245 )
2010
17
Current status in the management of uterine corpus cancer in Korea. ( 20922137 )
2010
18
Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. ( 20944170 )
2010
19
Positron emission tomography with the glucose analog [F]-fluoro-2-deoxy-D-glucose for evaluating pelvic lymph node metastasis in uterine corpus cancer: comparison with CT and MRI findings. ( 19215544 )
2009
20
Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. ( 18064567 )
2008
21
Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. ( 18201753 )
2008
22
FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. ( 16710101 )
2006
23
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. ( 16198401 )
2005
24
Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. ( 15581961 )
2004
25
Ethnic differences in uterine corpus cancer incidence and mortality in New Mexico's American Indians, hispanics and non-Hispanic whites. ( 9169158 )
1997
26
Identification of TP53 gene mutations in uterine corpus cancer with short follow-up. ( 9441778 )
1997
27
Correlation of C-myc and HER-2/neu amplification and expression with histopathologic variables in uterine corpus cancer. ( 7977518 )
1994
28
Estriol binding in uterine corpus cancer and in normal uterine tissues. ( 1869022 )
1991
29
Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway. ( 2384266 )
1990
30
A cohort analysis of breast cancer, uterine corpus cancer, and childbearing pattern in Norwegian women. ( 2273359 )
1990

Variations for Uterine Corpus Cancer

Copy number variations for Uterine Corpus Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 162862 22 22706138 22714284 Decreasing copy numb er GSTT1 Corpus uteri cancer

Expression for Uterine Corpus Cancer

Search GEO for disease gene expression data for Uterine Corpus Cancer.

Pathways for Uterine Corpus Cancer

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 ERBB2 ESR1 FBXW7 MYC PGR PIK3CA
2
Show member pathways
13.79 BRCA1 ERBB2 ESR1 MYC PIK3R2 PPP2R1A
3
Show member pathways
13.74 BRCA1 ERBB2 ESR1 MYC PGR PPP2R1A
4
Show member pathways
13.65 BRCA1 ERBB2 ESR1 MYC PIK3R2 PPP2R1A
5
Show member pathways
13.48 BRCA1 ERBB2 MYC PIK3CA PIK3R2 PPP2R1A
6
Show member pathways
13.39 ERBB2 FBXW7 PIK3CA PIK3R2 PPP2R1A TP53
7
Show member pathways
13.31 ERBB2 MYC PIK3CA PIK3R2 PPP2R1A TP53
8
Show member pathways
13.06 ERBB2 PIK3CA PIK3R2 PPP2R1A TP53
9
Show member pathways
13 ESR1 PGR PIK3CA PIK3R2 PPP2R1A
10
Show member pathways
12.86 BRCA1 ERBB2 MYC PIK3CA PIK3R2 PPP2R1A
11
Show member pathways
12.84 ERBB2 MYC PIK3CA PIK3R2 TP53
12
Show member pathways
12.76 MYC PIK3CA PIK3R2 TP53
13 12.75 ERBB2 ESR1 MYC PIK3CA PIK3R2 TP53
14
Show member pathways
12.7 ERBB2 PIK3CA PIK3R2 PPP2R1A TP53
15
Show member pathways
12.68 ERBB2 ESR1 PIK3CA PIK3R2 TP53
16
Show member pathways
12.67 BRCA1 ESR1 FBXW7 MYC TP53
17
Show member pathways
12.67 BRCA1 ERBB2 ESR1 PIK3CA PIK3R2 TP53
18
Show member pathways
12.56 ERBB2 MYC PIK3CA PIK3R2 TP53
19
Show member pathways
12.51 ERBB2 MYC PIK3CA PIK3R2 TP53
20 12.49 BRCA1 PPP2R1A S100A6 TP53
21
Show member pathways
12.48 ERBB2 PIK3CA PIK3R2 TP53
22
Show member pathways
12.43 PIK3CA PIK3R2 PPP2R1A TP53
23
Show member pathways
12.43 ERBB2 PIK3CA PIK3R2 TP53
24
Show member pathways
12.43 ERBB2 ESR1 MYC PIK3CA PIK3R2
25
Show member pathways
12.42 ERBB2 MYC PIK3CA PIK3R2 TP53
26 12.41 MYC PIK3CA PIK3R2 TP53
27
Show member pathways
12.39 BRCA1 ESR1 PIK3CA PIK3R2
28 12.39 BRCA1 ERBB2 MYC PIK3CA PIK3R2 TP53
29
Show member pathways
12.38 MYC PIK3CA PIK3R2 TP53
30
Show member pathways
12.34 PGR PIK3CA PIK3R2 PPP2R1A
31
Show member pathways
12.31 ERBB2 ESR1 PIK3CA PIK3R2
32 12.28 MYC PIK3CA PIK3R2 TP53
33
Show member pathways
12.22 BRCA1 ERBB2 ESR1 MYC PGR PIK3CA
34
Show member pathways
12.17 PIK3CA PIK3R2 PPP2R1A
35 12.16 MYC PIK3CA PIK3R2 TP53
36 12.15 MYC PIK3R2 TP53
37
Show member pathways
12.14 ERBB2 MYC PIK3CA PIK3R2 TP53
38
Show member pathways
12.14 BRCA1 ESR1 FBXW7 MYC PGR
39
Show member pathways
12.13 PIK3CA PIK3R2 TP53
40
Show member pathways
12.13 ERBB2 MYC PIK3CA PIK3R2
41
Show member pathways
12.11 MYC PIK3R2 TP53
42
Show member pathways
12.1 PIK3CA PIK3R2 TP53
43 12.1 ERBB2 ESR1 MYC PIK3CA PIK3R2 TP53
44 12.06 PIK3CA PIK3R2 TP53
45 12.06 MYC PIK3CA PIK3R2
46 12.06 ERBB2 MYC PIK3CA PIK3R2 TP53
47
Show member pathways
12.05 BRCA1 MYC PIK3CA PIK3R2 PPP2R1A
48 12.05 PIK3CA PIK3R2 PPP2R1A TP53
49
Show member pathways
12.04 MYC PIK3CA PIK3R2
50 12.04 MYC PIK3R2 TP53

GO Terms for Uterine Corpus Cancer

Cellular components related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.91 ERBB2 ESR1 FBXW7 PGR PIK3CA PIK3R2
2 cytoplasm GO:0005737 9.7 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
3 nucleus GO:0005634 9.36 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR
4 phosphatidylinositol 3-kinase complex GO:0005942 9.16 PIK3CA PIK3R2

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.88 BRCA1 ESR1 MYC PGR PIK3R2 TP53
2 positive regulation of gene expression GO:0010628 9.8 BRCA1 ERBB2 MYC TP53
3 protein deubiquitination GO:0016579 9.67 BRCA1 ESR1 MYC TP53
4 negative regulation of gene expression GO:0010629 9.62 ESR1 FBXW7 MYC PGR
5 vasculature development GO:0001944 9.51 FBXW7 PIK3CA
6 cellular response to estrogen stimulus GO:0071391 9.48 ESR1 MYC
7 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.46 BRCA1 TP53
8 positive regulation of protein kinase B signaling GO:0051897 9.46 ERBB2 ESR1 PIK3CA PIK3R2
9 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.43 ESR1 TP53
10 positive regulation of fibroblast proliferation GO:0048146 9.43 ESR1 MYC S100A6
11 phosphatidylinositol 3-kinase signaling GO:0014065 9.13 ERBB2 PIK3CA PIK3R2
12 phosphatidylinositol phosphorylation GO:0046854 8.92 ERBB2 ESR1 PIK3CA PIK3R2

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.8 BRCA1 ESR1 PGR S100A6 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.73 ESR1 MYC PGR TP53
3 enzyme binding GO:0019899 9.67 BRCA1 ESR1 PGR TP53
4 identical protein binding GO:0042802 9.63 BRCA1 ERBB2 ESR1 FBXW7 PGR TP53
5 protein phosphatase binding GO:0019903 9.5 ERBB2 PIK3R2 TP53
6 protein heterodimerization activity GO:0046982 9.35 ERBB2 MYC PIK3R2 PPP2R1A TP53
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 ERBB2 ESR1 PIK3CA PIK3R2
8 protein binding GO:0005515 10.03 BRCA1 ERBB2 ESR1 FBXW7 MYC PGR

Sources for Uterine Corpus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....